Novel human genes relating to respiratory diseases and obesity

Abstract

This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.

1 . An isolated antibody or epitope-binding fragment thereof which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9, wherein the antibody or epitope-binding fragment binding is to the SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9 portion of the polypeptide. 
     
     
         2 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to an immunogenic component comprising at least 30 amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9. 
     
     
         3 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to an immunogenic component comprising at least 50 amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9. 
     
     
         4 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to an immunogenic component comprising at least 100 amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9. 
     
     
         5 . The isolated antibody or epitope-binding fragment of  claim 1  which binds to a polypeptide having an amino acid sequence of at least 200 consecutive residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9 or an immunogenic component thereof. 
     
     
         6 . The isolated antibody or epitope-binding fragment of  claim 1 , which is immobilized on a solid support. 
     
     
         7 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to a polypeptide having an amino acid sequence of SEQ ID NO: 3. 
     
     
         8 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to a polypeptide having an amino acid sequence of SEQ ID NO: 5. 
     
     
         9 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to a polypeptide having an amino acid sequence of SEQ ID NO: 7. 
     
     
         10 . The isolated antibody or epitope-binding fragment of  claim 1 , which binds to a polypeptide having an amino acid sequence of SEQ ID NO: 9. 
     
     
         11 . The isolated antibody or epitope-binding fragment of  claim 1  which is a monoclonal antibody. 
     
     
         12 . The isolated antibody or epitope-binding fragment of  claim 1  which is a polyclonal antibody. 
     
     
         13 . The isolated antibody or epitope-binding fragment of  claim 1  which is a recombinant antibody. 
     
     
         14 . The isolated antibody or epitope-binding fragment of  claim 1  which is a chimeric antibody. 
     
     
         15 . The isolated antibody or epitope-binding fragment of  claim 1  which is a humanized antibody. 
     
     
         16 . The isolated antibody or epitope-binding fragment of  claim 1  bound to said polypeptide. 
     
     
         17 . A pharmaceutical composition comprising the isolated antibody or epitope-binding fragment of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         18 . An isolated antibody or epitope-binding fragment thereof which binds to a polypeptide having an amino acid sequence encoded by 50 or more consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 wherein the antibody or epitope-binding fragment binding is to the amino acid sequence encoded by 50 or more consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 portion of the polypeptide. 
     
     
         19 . The isolated antibody or epitope-binding fragment of  claim 18 , which binds to an immunogenic component comprising at least 30 amino acid residues encoded by consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8. 
     
     
         20 . The isolated antibody or epitope-binding fragment of  claim 18 , which binds to an immunogenic component comprising at least 50 amino acid residues encoded by consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8. 
     
     
         21 . The isolated antibody or epitope-binding fragment of  claim 18 , which binds to an immunogenic component comprising at least 100 amino acid residues encoded by consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8. 
     
     
         22 . The isolated antibody or epitope-binding fragment of  claim 18 , which is immobilized on a solid support. 
     
     
         23 . The isolated antibody or epitope-binding fragment of  claim 18  which is a monoclonal antibody. 
     
     
         24 . The isolated antibody or epitope-binding fragment of  claim 18  which is a polyclonal antibody. 
     
     
         25 . The isolated antibody or epitope-binding fragment of  claim 18  which is a recombinant antibody. 
     
     
         26 . The isolated antibody or epitope-binding fragment of  claim 18  which is a chimeric antibody. 
     
     
         27 . The isolated antibody or epitope-binding fragment of  claim 18  which is a humanized antibody. 
     
     
         28 . The isolated antibody or epitope-binding fragment of  claim 18  bound to said polypeptide. 
     
     
         29 . A pharmaceutical composition comprising the isolated antibody or epitope-binding fragment of  claim 18  and a pharmaceutically acceptable carrier.